...
首页> 外文期刊>The Journal of Steroid Biochemistry and Molecular Biology >1,25-Dihydroxyvitamin D3 up-regulates TLR10 while down-regulating TLR2, 4, and 5 in human monocyte THP-1
【24h】

1,25-Dihydroxyvitamin D3 up-regulates TLR10 while down-regulating TLR2, 4, and 5 in human monocyte THP-1

机译:1,25-二羟基维生素D3在人单核细胞THP-1中上调TLR10,同时下调TLR2、4和5

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In humans, there are ten Toll-like receptors (TLRs), among which TLR10 is the only orphan receptor whose function is unknown. In this study, we examined the effects of IFN-γ, LPS and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] on TLR10 expression of human monocyte THP-1 and compared them with those of other surface TLRs such as TLR2, 4 and 5 to differentiate TLR10 from other TLRs. Surface TLR10 expression on THP-1 was significantly enhanced by the addition of IFN-γ or LPS in a fashion similar to that of other TLRs. However, TLR10 expression was differentially regulated by 1,25(OH)2D3. Surface TLR10 expression on THP-1 was significantly enhanced at 24 h, reaching approximately two times the control level at 48 h after treatment with 100 nM 1,25(OH)2D 3, while that of TLR2, 4 and 5 decreased gradually in response to treatment over time. 1,25(OH)2D3 at concentrations above 1 nM markedly enhanced surface TLR10 expression, but concentrations below 1 nM did not. TLR10 mRNA expression was also increased by 1,25(OH)2D 3. We next screened for putative binding sites of nuclear vitamin D receptor (VDR) and its counterpart RXR-α within promoter of TLR genes using a transcription factor binding site-prediction program. The results revealed that TLR10 is the only receptor among the tested TLRs that has both a VDR and RXR-α binding site within its proximal promoter. To identify possible involvement of VDR/RXR in the 1,25(OH)2D3-induced TLR10 up-regulation, we engaged the VDR synthesis inhibitor, dexamethasone, and the RXR antagonist, 1,8-dihydroxyanthraquinone. We found that TLR10 up-regulation was significantly blocked with pre-treatment of these inhibitors. These findings indicate that surface TLR10 expression is differentially regulated by 1,25(OH)2D3 and mainly regulated at the transcriptional level via VDR/RXR-α. Overall, results presented herein suggest that TLR10 functions differently from other known surface TLRs under certain circumstances. Further study using primary cells is necessary to confirm the results of the present study.
机译:在人类中,有十种Toll样受体(TLR),其中TLR10是唯一一个功能未知的孤儿受体。在这项研究中,我们检查了IFN-γ,LPS和1,25-二羟基维生素D3 [1,25(OH)2D3]对人单核细胞THP-1 TLR10表达的影响,并将其与其他表面TLRs的影响进行了比较,例如TLR2、4和5将TLR10与其他TLR区别开来。通过添加IFN-γ或LPS,可以以类似于其他TLR的方式显着增强THP-1上的表面TLR10表达。但是,TLR10表达受到1,25(OH)2D3的差异调节。在用100 nM 1,25(OH)2D 3处理后,THP-1上的表面TLR10表达在24 h显着增强,在48 h达到对照水平的约两倍,而在响应中TLR2、4和5的表达逐渐降低随着时间的流逝。浓度高于1 nM的1,25(OH)2D3显着增强了表面TLR10表达,但浓度低于1 nM则没有。 TLR10 mRNA表达也增加了1,25(OH)2D3。我们接下来使用转录因子结合位点预测技术筛选了TLR基因启动子中的核维生素D受体(VDR)及其对应的RXR-α的假定结合位点。程序。结果表明,TLR10是受测TLR中唯一在其近端启动子中同时具有VDR和RXR-α结合位点的受体。为了确定VDR / RXR可能参与1,25(OH)2D3诱导的TLR10上调,我们使用了VDR合成抑制剂地塞米松和RXR拮抗剂1,8-二羟基蒽醌。我们发现,用这些抑制剂进行预处理可明显阻止TLR10的上调。这些发现表明表面TLR10表达受1,2,5(OH)2D3的差异调节,并且主要通过VDR /RXR-α在转录水平上被调节。总体而言,本文提出的结果表明,在某些情况下,TLR10的功能不同于其他已知的表面TLR。为了证实本研究的结果,有必要使用原代细胞进行进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号